18813-71-3

Basic information

• Product Name: 6-bromo-1-methyl-9H-beta-carboline
• CAS NO: 18813-71-3
• Molecular Formula: C₁₂H₉BrN₂
• Molecular Weight: 261.1173
• Mol File: 18813-71-3.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 438.2°C at 760 mmHg
• Flash Point: 218.8°C
• Density: 1.615g/cm³
• Vapor Pressure: 1.81E-07mmHg at 25°C
• Refractive Index: 1.766
• CAS DataBase Reference: 6-bromo-1-methyl-9H-beta-carboline(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-1-methyl-9H-beta-carboline(18813-71-3)
• EPA Substance Registry System: 6-bromo-1-methyl-9H-beta-carboline(18813-71-3)

Safety Data

• Hazardous Substances Data: 18813-71-3(Hazardous Substances Data)

Usage

General Description

6-bromo-1-methyl-9H-beta-carboline is a chemical compound that belongs to the class of beta-carbolines. It is a derivative of beta-carboline, which is a heterocyclic compound known for its psychoactive properties. This specific compound contains a bromine atom and a methyl group attached to the beta-carboline ring. It has been studied for its potential pharmacological activities, including its effects on the central nervous system and potential therapeutic applications. Additionally, beta-carbolines have been studied for their potential role in neurodegenerative disorders and as ligands for various receptors in the brain. The specific properties and potential applications of 6-bromo-1-methyl-9H-beta-carboline are the subject of ongoing research and may have implications for drug development and neuroscience.

Upstream product

• 73-22-3 L-Tryptophan 
• 3156-51-2 3-[(E)-2-nitroeth-1-enyl]-1H-indole 
• 120-72-9 indole 
• 487-89-8 Indole-3-carboxaldehyde 
• 486-84-0 harmane 
• 61-54-1 tryptamine 
• 2506-10-7 eleagnine 
• 38314-91-9 6-nitro-1-methyl-9H-pyrido[3,4-b]indole 
• 6548-09-0 5-bromo-DL-tryptophan 
• 113679-50-8 6-bromo-1-methyl-2,3,4,9-tetrahydro-1H-β-carboline-3-carboxylic acid 
• 102206-91-7 1-methyl-9H-β-carbolin-6-ylamine 

Downstream Products

• 1374751-67-3 6-phenyl-1-methyl-beta-carboline 
• 1374751-68-4 6-(3-chlorophenyl)-1-methyl-9H-pyrido[3,4-b]indole 
• 1374751-87-7 6-(3-cyanophenyl)-1-methyl-9H-pyrido[3,4-b]indole 
• 1374751-76-4 6-(3-(aminomethyl)phenyl)-1-methyl-9H-pyrido[3,4-b]indole 
• 1374751-77-5 6-(3-(acetamidomethyl)phenyl)-1-methyl-9H-pyrido[3,4-b]indole 
• 1374752-11-0 1-ethyl-3-(3-(1-methyl-9H-pyrido[3,4-b]indol-6-yl)benzyl)urea 
• 1374752-45-0 N-Boc-(3-(1-methyl-9H-pyrido[3,4-b]indol-6-yl)phenyl)methanamine 

Relevant articles and documents

Evaluation of canthinone alkaloids as cerebral protective agents

Considerable attention has been paid to cerebral protective drugs as a potential therapy for dementia. Screening of a natural compound library here resulted in identification of five canthinone alkaloids, viz., picrasidine L (1), picrasidine O (2), eurycomine E (3), 3-ethyl-canthin-5,6-dione (4), and 3-ethyl-4-methoxy-canthin-5,6-dione (5), as novel cerebral protective agents. The structure–activity relationship indicated that C-4, C-9, and N-3 substitutions greatly affected their cerebral protective effect. Among these, compound 2 exhibited a cerebral protective effect through suppressing neuronal hyperexcitability due to an increase in the excitatory neurotransmitter glutamic acid. Furthermore, compound 2 did not affect heart rate and mean systolic blood pressure. This investigation suggests that compound 2 has potential for further development as a cerebral protective drug.

Brominated β-carbolines from the marine hydroid Aglaophenia pluma Linnaeus

-

SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS

Substituted pyrido[3,4-b]indoles and their use as pharmaceuticals The present invention relates to 8-aryl-substituted and 8-heteroaryl-substituted 9H-pyrido[3,4-b]indoles of the formula I, in which A, E, G, R1 to R6 and R10 are as defined in the claims, which stimulate chondrogenesis and cartilage matrix synthesis and can be used in the treatment of cartilage disorders and conditions in which a regeneration of damaged cartilage is desired, for example joint diseases such as osteoarthritis. The invention furthermore relates to processes for the synthesis of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.